v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities:      
Net income $ 18,241 $ 15,412  
Adjustments to reconcile net income to net cash provided by operating activities:      
Provision for credit losses 400 200 $ (800)
Depreciation and amortization of premises and equipment 591 564  
Amortization of intangibles 1,298 1,500  
Net accretion of securities (1,374) (1,090)  
Amortization of stock-based compensation 551 554  
Accretion of purchase accounting valuations (1,017) (1,170)  
Net change in deferred loan fees and costs (239) (133)  
Change in fair value of MSR and other investments (693) 388  
Loss from sale and disposal of premises and equipment   170  
Net gain on sale of OREO and valuation allowance   (47)  
Proceeds from sales of mortgage loans 29,241 18,516  
Originations of mortgage loans held for sale (28,495) (16,578)  
Gain on sales of mortgage loans (334) (219)  
Realized loss on sale of securities   34  
Undistributed income of Ansay joint venture (1,181) (979)  
Net earnings on life insurance (407) (405)  
Decrease (increase) in other assets 973 (664)  
Increase (decrease) in other liabilities (11,389) (14,724)  
Net cash provided by operating activities 6,166 1,329  
Cash flows from investing activities:      
Activity in securities available for sale and held to maturity: Sales   10,206  
Activity in securities available for sale and held to maturity: Maturities, prepayments, and calls 256,762 79,087  
Activity in securities available for sale and held to maturity: Purchases (194,612) (93,687)  
Net increase in loans (30,417) (38,551)  
Dividends received from Ansay 635 533  
Proceeds from sale of OREO   261  
Proceeds from life insurance 1,328    
Proceeds from sale of premises and equipment 1    
Purchases of premises and equipment (2,154) (778)  
Net cash provided by (used in) investing activities 31,543 (42,929)  
Cash flows from financing activities:      
Net increase (decrease) in deposits 13,140 (16,854)  
Net decrease in securities sold under repurchase agreements   (75,747)  
Repayment of notes payable (508)    
Repayment of junior subordinated debentures   (4,124)  
Dividends paid (4,491) (3,541)  
Proceeds from sales of common stock 64 55  
Repurchase of common stock (6,381) (22,283)  
Net cash provided by (used in) financing activities 1,824 (122,494)  
Net increase (decrease) in cash and cash equivalents 39,533 (164,094)  
Cash and cash equivalents at beginning of period 261,332 247,468 247,468
Cash and cash equivalents at end of period 300,865 83,374 $ 261,332
Cash paid during the year for:      
Interest 18,724 15,779  
Supplemental schedule of noncash activities:      
MSR resulting from sale of loans 325 189  
Change in unrealized gains and losses on investment securities available for sale, net of tax $ 747 $ (665)